Evidence map›Paper›PMID 39416221›Full record

ArticlebioRxiv : the preprint server for biology2024

Heterozygous and generalist MxA super-restrictors overcome breadth-specificity tradeoffs in antiviral restriction.

Rechel A Geiger, Damini Khera, Jeannette L Tenthorey, Georg Kochs, Laura Graf, Michael Emerman, Harmit S Malik

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Rechel A GeigerMedical Scientist Training Program, University of Washington School of Medicine, Seattle, WA, USA 98195.ORCID 0000-0001-7748-9367
Damini KheraDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA 98109.
Jeannette L TenthoreyDepartment of Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA 94158.ORCID 0000-0003-0175-080X
Georg KochsFaculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0003-0187-559X
Laura GrafInstitute of Virology, Medical Center, University of Freiburg, 79104 Freiburg, Germany.
Michael EmermanDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA 98109.ORCID 0000-0002-4181-6335
Harmit S MalikDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA 98109.ORCID 0000-0001-6005-0016

Funding

Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
INTERDISCIPLINARY TRAINING IN GENOMIC SCIENCEST32HG000035 · NHGRI · UNIVERSITY OF WASHINGTON · PI Bruce Colston Trapnell · 1995 to 2026
$24.2M
NHGRI NIH HHS T32 HG000035NIAID NIH HHS U54 AI170792
6 · The paper itself

Abstract

Antiviral restriction factors such as MxA (myxovirus resistance protein A) inhibit a broad range of viruses. However, they face the challenge of maintaining this breadth as viruses evolve to escape their defense. Viral escape drives restriction factors to evolve rapidly, selecting for amino acid changes at their virus-binding interfaces to regain defense. How do restriction factors balance the breadth of antiviral functions against the need to evolve specificity against individual escaping viruses? We explored this question in human MxA, which uses its rapidly evolving loop L4 as the specificity determinant for

Identifiers

PMID39416221
PMCPMC11482965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.